ABCC1 p.Arg1367Ala
Predicted by SNAP2: | A: D (91%), C: D (91%), D: D (95%), E: D (95%), F: D (95%), G: D (95%), H: D (91%), I: D (91%), K: D (91%), L: D (91%), M: D (91%), N: D (91%), P: D (95%), Q: D (91%), S: D (91%), T: D (91%), V: D (91%), W: D (95%), Y: D (95%), |
Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Expression and function of human MRP1 (ABCC1) is d... J Biol Chem. 2011 Mar 4;286(9):7202-13. Epub 2010 Dec 20. Iram SH, Cole SP
Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2.
J Biol Chem. 2011 Mar 4;286(9):7202-13. Epub 2010 Dec 20., 2011-03-04 [PMID:21177244]
Abstract [show]
Multidrug resistance protein 1 (MRP1) is an ATP-binding cassette transporter that effluxes drugs and organic anions across the plasma membrane. The 17 transmembrane helices of MRP1 are linked by extracellular and cytoplasmic loops (CLs), but their role in coupling the ATPase activity of MRP1 to the translocation of its substrates is poorly understood. Here we have examined the importance of CL5 by mutating eight conserved charged residues and the helix-disrupting Gly(511) in this region. Ala substitution of Lys(513), Lys(516), Glu(521), and Glu(535) markedly reduced MRP1 levels. Because three of these residues are predicted to lie at the interface of CL5 and the second nucleotide binding domain (NBD2), a critical role is indicated for this region in the plasma membrane expression of MRP1. Further support for this idea was obtained by mutating NBD2 amino acids His(1364) and Arg(1367) at the CL5 interface, which also resulted in reduced MRP1 levels. In contrast, mutation of Arg(501), Lys(503), Glu(507), Arg(532), and Gly(511) had no effect on MRP1 levels. Except for K503A, however, transport by these mutants was reduced by 50 to 75%, an effect largely attributable to reduced substrate binding and affinity. Studies with (32)P-labeled azido-ATP also indicated that whereas ATP binding by the G511I mutant was unchanged, vanadate-induced trapping of azido-ADP was reduced, indicating changes in the catalytic activity of MRP1. Together, these data demonstrate the multiple roles for CL5 in the membrane expression and function of MRP1.
Comments [show]
None has been submitted yet.
No. Sentence Comment
51 To engineer mutations of His1364 and Arg1367 in NBD2, a 0.8-kb EcoRI/KpnI fragment of MRP1 in pBluescriptSK(ϩ) was used as the template with the following mutagenic primers (substituted nucleotides are underlined): H1364A, 5Ј-GAT CGG CCT GGC CGA CCT CCG C-3Ј; and R1367A, 5Ј-CTG CAC GAC CTC GCC TTC AAG ATC AC-3Ј.
X
ABCC1 p.Arg1367Ala 21177244:51:282
status: NEW158 To test this hypothesis, mutants H1049A, H1364A, and R1367A were generated, and the levels of the mutant proteins in HEK293T cells determined as described above.
X
ABCC1 p.Arg1367Ala 21177244:158:53
status: NEW159 As observed for the CL5 mutant K516A, the NBD2 mutant R1367A was not detectable by immunoblot analysis (Fig. 5C).
X
ABCC1 p.Arg1367Ala 21177244:159:54
status: NEW178 Homology models and levels of MRP1 mutants H1049A, H1364A, and R1367A.
X
ABCC1 p.Arg1367Ala 21177244:178:63
status: NEW